These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22573668)

  • 1. R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures.
    Cepeda-Prado E; Popp S; Khan U; Stefanov D; Rodríguez J; Menalled LB; Dow-Edwards D; Small SA; Moreno H
    J Neurosci; 2012 May; 32(19):6456-67. PubMed ID: 22573668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
    Wade A; Jacobs P; Morton AJ
    Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
    Hickey MA; Reynolds GP; Morton AJ
    J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
    Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
    J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.
    Rattray I; Smith EJ; Crum WR; Walker TA; Gale R; Bates GP; Modo M
    PLoS One; 2013; 8(12):e84726. PubMed ID: 24367693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy.
    Sawiak SJ; Wood NI; Morton AJ
    J Huntingtons Dis; 2016 Oct; 5(3):271-283. PubMed ID: 27662335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease.
    Fisher SP; Black SW; Schwartz MD; Wilk AJ; Chen TM; Lincoln WU; Liu HW; Kilduff TS; Morairty SR
    Brain; 2013 Jul; 136(Pt 7):2159-72. PubMed ID: 23801738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
    Dufour BD; McBride JL
    Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence from the R6/2 Mouse Model of Huntington's Disease for Using Abnormal Brain Metabolism as a Biomarker for Evaluating Therapeutic Approaches for Treatment.
    Parievsky A; Cepeda C; Levine MS
    Future Neurol; 2012; 7(5):527-530. PubMed ID: 25892970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease.
    Sjögren M; Soylu-Kucharz R; Dandunna U; Stan TL; Cavalera M; Sandelius Å; Zetterberg H; Björkqvist M
    Neurobiol Dis; 2019 Dec; 132():104560. PubMed ID: 31419548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced cerebral branched-chain amino acid metabolism in R6/2 mouse model of Huntington's disease.
    Andersen JV; Skotte NH; Aldana BI; Nørremølle A; Waagepetersen HS
    Cell Mol Life Sci; 2019 Jun; 76(12):2449-2461. PubMed ID: 30830240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy.
    Tsang TM; Woodman B; McLoughlin GA; Griffin JL; Tabrizi SJ; Bates GP; Holmes E
    J Proteome Res; 2006 Mar; 5(3):483-92. PubMed ID: 16512662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
    Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
    J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.
    Menalled LB; Kudwa AE; Oakeshott S; Farrar A; Paterson N; Filippov I; Miller S; Kwan M; Olsen M; Beltran J; Torello J; Fitzpatrick J; Mushlin R; Cox K; McConnell K; Mazzella M; He D; Osborne GF; Al-Nackkash R; Bates GP; Tuunanen P; Lehtimaki K; Brunner D; Ghavami A; Ramboz S; Park L; Macdonald D; Munoz-Sanjuan I; Howland D
    PLoS One; 2014; 9(6):e99520. PubMed ID: 24955833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.
    Duarte AI; Sjögren M; Santos MS; Oliveira CR; Moreira PI; Björkqvist M
    Sci Rep; 2018 Jun; 8(1):8961. PubMed ID: 29895889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
    Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
    Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington's disease.
    Puginier E; Bharatiya R; Chagraoui A; Manem J; Cho YH; Garret M; De Deurwaerdère P
    Neurochem Int; 2019 Sep; 128():186-195. PubMed ID: 31054882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.